This article is more than 5 years old. Information may no longer be current.
VIDEO: Addition of brentuximab vedotin to salvage chemotherapy ‘sets stage’ for future studies
Click Here to Manage Email Alerts
SAN DIEGO — The addition of brentuximab vedotin to salvage chemotherapy before autologous stem cell transplantation may safely and effectively treat patients with relapsed or refractory classical Hodgkin lymphoma, Ryan D. Cassaday, MD, of Seattle Cancer Care Alliance, told HemOnc Today at the ASH Annual Meeting and Exposition.
Sixteen patients (median age, 32 years) with relapsed or primary refractory CD30–positive classical Hodgkin lymphoma received 1.5 mg/kg brentuximab vedotin (Adcetris, Seattle Genetics) on days 1 and 8 of each cycle with ICE chemotherapy, which consists of ifosfamide, carboplatin and etoposide.
Researchers reported a 94% overall response rate, an 88% complete response rate by investigator assessment and a 69% complete response rate by central independent radiographic review.
Grade 3 to 4 adverse events included neuropathy (31%), thrombocytopenia (25%), neutropenia (12%), lymphopenia (12%) and anemia (12%).
“It’s too early to make any sweeping conclusions about how this regimen is going to potentially work, or be practice-changing,” said Cassaday, assistant professor of medicine at University of Washington School of Medicine and assistant member of the clinical research division at Fred Hutchinson Cancer Research Center. “We’re certainly encouraged by the initial results. We are about halfway through our accrual, if we can continue to see these kind of response rates, it potentially sets the stage for larger studies to be a bit more definitive that might allow us to incorporate brentuximab vedotin earlier on in the treatment of Hodgkin lymphoma.” – by Kristie L. Kahl
Reference:
Cassaday RD, et al. Abstract 1834. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.
Disclosure: Cassaday reports no relevant financial disclosures.